Zisowsky J - Search Results

1

Drug Development for Pediatric Populations: Regulatory Aspects.

Zisowsky J, Krause A, Dingemanse J. Zisowsky J, et al. Pharmaceutics. 2010 Nov 29;2(4):364-388. doi: 10.3390/pharmaceutics2040364. Pharmaceutics. 2010. PMID: 27721363 Free PMC article. Review.

2

Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.

Zisowsky J, Fuseau E, Bruderer S, Krause A, Dingemanse J. Zisowsky J, et al. Eur J Clin Pharmacol. 2014 Apr;70(4):409-19. doi: 10.1007/s00228-014-1647-4. Epub 2014 Jan 24. Eur J Clin Pharmacol. 2014. PMID: 24458541 Clinical Trial.

3

Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection.

Krause A, Zisowsky J, Strasser DS, Gehin M, Sidharta PN, Groenen PMA, Dingemanse J. Krause A, et al. Among authors: zisowsky j. Clin Pharmacokinet. 2016 Jul;55(7):813-821. doi: 10.1007/s40262-015-0354-3. Clin Pharmacokinet. 2016. PMID: 26692193 Clinical Trial.

4

Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Zisowsky J, Géhin M, Kusic-Pajic A, Krause A, Beghetti M, Dingemanse J. Zisowsky J, et al. Paediatr Drugs. 2017 Apr;19(2):121-130. doi: 10.1007/s40272-016-0206-0. Paediatr Drugs. 2017. PMID: 28078552

5

Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.

Krause A, Zisowsky J, Dingemanse J. Krause A, et al. Among authors: zisowsky j. Pulm Pharmacol Ther. 2018 Apr;49:140-146. doi: 10.1016/j.pupt.2018.02.005. Epub 2018 Feb 28. Pulm Pharmacol Ther. 2018. PMID: 29501590 Clinical Trial.

6

A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.

Géhin M, Strasser DS, Zisowsky J, Farine H, Groenen PM, Dingemanse J, Sidharta PN. Géhin M, et al. Among authors: zisowsky j. J Clin Pharmacol. 2015 Jul;55(7):787-97. doi: 10.1002/jcph.478. Epub 2015 Mar 30. J Clin Pharmacol. 2015. PMID: 25655470 Clinical Trial.

7

Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.

Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Hoch M, et al. Among authors: zisowsky j. Pharmacology. 2012;89(1-2):53-7. doi: 10.1159/000335367. Epub 2012 Feb 1. Pharmacology. 2012. PMID: 22302127 Clinical Trial.

8

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake.

Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Keunecke A, et al. Among authors: zisowsky j. Br J Clin Pharmacol. 2020 Dec;86(12):2362-2376. doi: 10.1111/bcp.14334. Epub 2020 Jun 10. Br J Clin Pharmacol. 2020. PMID: 32358822 Free PMC article.

9

Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.

Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, Jaehde U. Zisowsky J, et al. Biochem Pharmacol. 2007 Jan 15;73(2):298-307. doi: 10.1016/j.bcp.2006.10.003. Epub 2006 Oct 10. Biochem Pharmacol. 2007. PMID: 17097621

10

Assessment of platinum sensitivity in human tumor cells.

Zisowsky J, Becker A, Weykam S, Kassack M, Jaehde U. Zisowsky J, et al. Int J Clin Pharmacol Ther. 2003 Dec;41(12):612-3. doi: 10.5414/cpp41612. Int J Clin Pharmacol Ther. 2003. PMID: 14692716 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters